Trial Profile
Continuous administration test from the Phase I/II clinical trials in hemophilia A patient of ACE910
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Feb 2022
Price :
$35
*
At a glance
- Drugs Emicizumab (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 05 Jun 2020 Results (n=389) of a population pharmacokinetics and exploratory exposure analysis from six clinical studies: HAVEN1, HAVEN2, HAVEN3, HAVEN4, JapicCTI-121934 and JapicCTI-132195 published in the Clinical Pharmacokinetics
- 09 Oct 2018 Planned number of patients changed to 16.